In the last trading session, 1.29 million Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) shares changed hands as the company’s beta touched 0.35. With the company’s per share price at $0.42 changed hands at $0.01 or 1.21% during last session, the market valuation stood at $4.73M. CYCC’s last price was a discount, traded about -852.38% off its 52-week high of $4.00. The share price had its 52-week low at $0.31, which suggests the last value was 26.19% up since then. When we look at Cyclacel Pharmaceuticals Inc’s average trading volume, we note the 10-day average is 12.42 million shares, with the 3-month average coming to 3.54 million.
Analysts gave the Cyclacel Pharmaceuticals Inc (CYCC) stock a consensus recommendation rating of Buy, calculated at a mean rating of 3.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended CYCC as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Cyclacel Pharmaceuticals Inc’s EPS for the current quarter is expected to be 0.
Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) trade information
Instantly CYCC was in green as seen at the end of in last trading. With action 13.21%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 11.68%, with the 5-day performance at 13.21% in the green. However, in the 30-day time frame, Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) is 7.67% up. Looking at the short shares, we see there were 66765.0 shares sold at short interest cover period of 0.03 days.
The consensus price target for the stock as assigned by Wall Street analysts is 1, meaning bulls need an upside of 58.0% from its current market value. According to analyst projections, CYCC’s forecast low is 1 with 1 as the target high. To hit the forecast high, the stock’s price needs a -138.1% plunge from its current level, while the stock would need to soar -138.1% for it to hit the projected low.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 32.13%.
CYCC Dividends
Cyclacel Pharmaceuticals Inc is expected to release its next quarterly earnings report in February.
Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 4.82% of Cyclacel Pharmaceuticals Inc shares while 18.03% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 18.94%.
Among Mutual Funds, the top two as of Nov 30, 2024 were Fidelity Extended Market Index Fund and Vanguard Extended Market Index Fund . With 8.96 shares estimated at $3761.0 under it, the former controlled 0.14% of total outstanding shares. On the other hand, Vanguard Extended Market Index Fund held about 0.09% of the shares, roughly 5.8 shares worth around $2433.0.
